IDO inhibitors

A compound of formula I

• wherein:
• Y is N, CH or CF;
• V is N, CH or CF;
• R1 is —COOH, —COOC1-C6 alkyl, —CONH2, —CN, optionally substituted 5 or 6 membered heterocyclyl having 1-4 ring vertices independently selected from O, N, S, 5 or 6 membered optionally substituted heteroaryl having 1-4 ring vertices independently selected from O, N, S, —NHCONHR13, —CONHSO2R14, —CONHCOR13, —SO2NHCOR13, —CONR13, —CONHSO2NR13R14, —SO2NHR13, —NHCONHSO2R13, —CHCF3OH, —COCF3, —CR2R3OH, or —NHSO2R13;
• R13 is H, optionally substituted C1-C10 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, optionally substituted 5-6 membered heterocyclyl having 1-4 ring vertices independently selected from O, N, S, optionally substituted phenyl, or optionally substituted 5-6 membered heteroaryl having 1-4 vertices independently selected from O, N, S;
• R14 is H, optionally substituted C1-C10 alkyl, phenyl, or C3-8 cycloalkyl;
• R2 and R3 are independently -hydrogen, optionally substituted C1-C10 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted phenyl;
• or
• R2 and R3 are taken together with the carbon to which they are attached to form an optionally substituted 3- to 6-membered carbocyclic or heterocyclic ring;
• R4 and R5 are independently H, optionally substituted C1-C10 alkyl, optionally substituted C1-C10-alkoxy-C1-C10-alkyl, optionally substituted C1-C10 alkoxy, optionally substituted aryl, optionally substituted aryl-C1-C10-alkyl, optionally substituted 5- to 8-membered heteroaryl containing 0-3 heteroatoms selected form N, S and O, optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclyl containing 0-3 heteroatoms selected form N, S and O;
• or
• R4 and R5 are taken together with the nitrogen to which they are attached to form a 4- to 8-membered optionally substituted heterocyclic ring containing 0-3 additional heteroatoms selected from —N—, —S— and —O—;
• or
• R4 and R5 are taken together with the nitrogen to which they are attached to form a 6- to 10-membered optionally substituted heterobicyclic ring containing 0-3 additional heteroatoms selected from —N—, —S—, and —O—;
• R6 is optionally substituted 5 or 6 membered aryl, optionally substituted 5 or 6 membered heteroaryl having 1 to 4 ring vertices selected from O, N, S, optionally substituted C3-C8 cycloalkyl optionally substituted 9 to 10 membered fused bicyclic heterocyclyl having 1 to 4 ring vertices independently selected from O, N, S, 9 to 10 membered fused bicyclic heteroaryl having 1 to 4 vertices independently selected from O, N, S or —COR7;
• R7 is optionally substituted —CR2R3— 5 or 6 membered aryl, optionally substituted —CR2R3— 5 or 6 membered heteroaryl, —CR2R3— 3 to 6 membered heterocyclyl, optionally substituted 5 or 6 membered aryl, optionally substituted 5 or 6 membered heteroaryl, optionally substituted C3-C8 cycloalkyl, or optionally substituted 3 to 6 membered heterocyclyl;
• and
• Rx and Ry are each independently H, optionally substituted C1-C10 alkyl, optionally substituted C1-C10 alkoxy, or optionally substituted C3-C8 cycloalkyl;
• or
• Rx and Ry are taken together with the carbon to which they are attached to form a 3- to 7-membered heterocyclic ring containing 0-3 additional heteroatoms selected from —N—, —S— and —O—;
• and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.